Atropos Health Raises $33M to Scale the Automation of High-Quality, Personalized Real-World Evidence Leveraging Generative AI
May 23 2024 - 9:24AM
Business Wire
The Company is Also Forging Strategic
Partnerships With Pharmaceutical Companies and Vertically
Integrated Healthcare Companies to Drive Evidence Adoption in
Oncology and other Specialty areas
Atropos Health, the pioneer in translating real-world
clinical data into high-quality personalized real-world evidence
for care, today announced a $33 million Series B on the heels of
the adoption of its Generative AI platform (GENEVA OS™) by
healthcare institutions, data platforms, research institutions,
life sciences companies and more. The funding was led by Valtruis,
with participation from new strategic investors including Cencora
Ventures, McKesson Ventures, and Merck Global Health Innovation
Fund, along with existing investors Breyer Capital, Emerson
Collective, and Presidio Ventures.
Atropos Health was founded in 2019 by Brigham Hyde Ph.D., Nigam
Shah MBBS, Ph.D., and Saurabh Gombar M.D., Ph.D., originally
developed as the “Green Button” project at Stanford University. The
trio are leaders in applications of AI and real-world evidence
research in healthcare, and on a mission to democratize access to
high-quality real-world evidence (RWE) as a means to improve
decision making and outcomes in healthcare. Since then, the company
has emerged as a leader in the application of generative AI thanks
to unique vertical user experiences like ChatRWD™ which reduces the
time to produce high-quality publication-grade real-world evidence
from months to minutes through a chat-based AI co-pilot.
“As excitement over the application of Generative AI technology
in healthcare turns from potential to practical applications, the
focus of providers, life sciences, and other healthcare
stakeholders turns to quality, transparency, and automation backed
by tangible ROI. For decades, high-quality clinical evidence has
served as the currency of value in healthcare. Atropos Health is
built on investment in scaling the production of high-quality,
transparent, and now real-time evidence production that matches the
standards of the clinical and research communities,” said Brigham
Hyde, CEO and Co-Founder of Atropos Health. “This funding round,
which includes multiple major strategic stakeholders in the
healthcare ecosystem, is validation that our platform is rapidly
becoming the standard not only for automation and user experience,
but also as the trusted quality layer between healthcare data and
the critical evidence needed to better inform patient care,
research, and policy.”
Investing in Real-World Evidence for Value-Based Care
Decision-Making
With this funding, Atropos Health plans to further its stake in
value-based care. The company’s portfolio of evidence-generating
applications supports whole-person care and value-based performance
and has long been utilized by Atropos Health partners including
Arcadia. Through Atropos Health, healthcare organizations are able
to accelerate appropriate clinical decision-making to drive
high-value, low-cost care for patients based on their unique
physiology. To drive this mission further, Atropos Health is
welcoming value-based care veteran Mike Spadafore to its board.
“For nearly 15 years, I’ve had a front-row seat to value-based
care's evolution and positive impact on patients, physicians, and
communities. I am excited about Atropos Health and its ability to
automate personalized, real-world evidence at scale for both
providers and researchers,” said Spadafore, Managing Director of
Valtruis. “Atropos Health has the potential to dramatically improve
existing workflows across both life sciences and health systems, in
turn improving clinician decision-making and driving better
outcomes for patients. We are thrilled to partner with Atropos in
this journey.”
Expanding the Atropos Evidence™ Network Including Vertical
Integrations with Oncology and Specialty areas
As a part of this round, Atropos Health will enter into
strategic relationships with partners from life sciences and
vertically integrated healthcare players. Through Cencora, a
leading global pharmaceutical solutions organization, Atropos
Health will bring its real-world evidence platform to oncology and
specialty care. Evidence for care is critical in the rapidly
evolving treatment landscape for oncology, where the stakes are
high for cancer patients. Now, oncologists and researchers can
leverage the Atropos Evidence Network of millions of anonymized
patient data converted to high-quality evidence to inform their
decision-making process. In turn, pharmaceutical customers of
Atropos Health, such as Janssen Research & Development, LLC
(Janssen), a Johnson & Johnson company, can leverage this
evidence network to drive critical R&D initiatives and
accelerate the time of the development of the next treatment.
“Atropos Health addresses a very real problem that both health
systems and pharmaceutical manufacturers face in turning medical
data into insights in a timely, predictable, and cost-effective
manner.” said Michelle Snyder, Partner at McKesson Ventures. “As
leading industry players increasingly recognize the value of having
the right data, rather than just having the most data, Atropos
Health stands out in its ability to understand and score datasets
in a compliant and secure manner in order to accelerate research
and improve patient outcomes.”
Expanding Investment in Atropos Health Generative Application
ChatRWD
Launched in Beta in Q4 of 2023, ChatRWD cuts production of high
quality real-world evidence down from months to minutes through
clinical and research friendly chat based user experience. While
the speed of ChatRWD is already revolutionary, accuracy and
transparency of results is a core tenant of Atropos Health
foundation. Built on the core technology GENEVA OS, ChatRWD is a
LLM independent framework (enabling institutions to maintain LLM
security and integrity) that is built to eliminate hallucination
risk that is unacceptable in the clinical evidence arena. A pending
publication will further outline this approach and the benefits to
accuracy in the generation of evidence. Investment in this round
will support the full launch of ChatRWD with the potential to
democratize high-quality, accurate, transparent, and personalized
real-world evidence for everyone.
About Atropos Health
Atropos Health is the developer of GENEVA OS™, the operating
system for rapid healthcare evidence across a robust network of
real-world data. Healthcare and life science organizations work
with Atropos Health to close evidence gaps from bench to bedside,
improving individual patient outcomes with data-driven care,
expediting research that advances the field of medicine, and more.
We aim to transform healthcare with timely, relevant real-world
evidence.
To learn more about Atropos Health, visit www.atroposhealth.com
or connect through LinkedIn or follow on X (Twitter)
@AtroposHealth.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240523484154/en/
Bruno Solari atropos@solcomms.co